Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ironwood Pharmaceuticals Inc (IRWD)
Price$4.26Cached quote
Net income
2009
2010
2011
2012
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M | $346.6M | $298.3M | $274.0M | $149.6M | $76.4M | $22.9M | $150.2M | $65.9M | $43.9M | $34.3M |
| Gross profit | — | — | — | $410.6M | $413.8M | $386.4M | $404.5M | $313.9M | $279.2M | $272.1M | $149.5M | $71.1M | $15.7M | $149.3M | — | — | — |
| Gross margin | — | — | — | 100.00% | 100.00% | 99.19% | 94.43% | 90.55% | 93.60% | 99.32% | 99.99% | 93.08% | 68.52% | 99.36% | — | — | — |
| Research & development | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M | $88.1M | $115.0M | $101.1M | $88.1M | $139.5M | $108.7M | $101.9M | $102.4M | $113.5M | $86.1M | $77.5M | $76.1M |
| Operating expenses | $197.6M | $258.3M | $1.39B | $160.3M | $181.5M | $246.6M | $308.3M | $497.3M | $313.6M | $325.8M | $251.6M | $245.8M | $274.9M | $223.0M | $132.0M | $104.6M | $95.1M |
| Operating income | $98.5M | $93.1M | −$945.4M | $250.3M | $232.3M | $142.9M | $120.1M | −$150.7M | −$15.4M | −$51.9M | −$102.1M | −$169.4M | −$252.0M | −$72.8M | −$66.1M | −$60.8M | −$60.8M |
| Operating margin | 33.26% | 26.50% | −213.54% | 60.97% | 56.13% | 36.70% | 28.04% | −43.47% | −5.15% | −18.93% | −68.26% | −221.58% | −1,101.36% | −48.43% | −100.41% | −138.55% | −177.20% |
| EBITDA | $99.6M | $94.3M | −$944.2M | $251.7M | $233.8M | $145.2M | $125.7M | −$146.8M | −$9.0M | −$41.6M | −$90.5M | −$157.0M | −$240.3M | −$61.4M | −$56.1M | −$54.6M | −$56.1M |
| EBITDA margin | 33.63% | 26.84% | −213.27% | 61.31% | 56.50% | 37.29% | 29.35% | −42.34% | −3.00% | −15.18% | −60.48% | −205.45% | −1,050.10% | −40.89% | −85.23% | −124.51% | −163.32% |
| Net income | $24.0M | $880,000 | −$1.00B | $175.1M | $528.4M | $106.2M | $21.5M | −$282.4M | −$116.9M | −$81.7M | −$142.7M | — | — | −$72.6M | −$64.9M | −$51.9M | −$73.3M |
| Net profit margin | 8.11% | 0.25% | −226.37% | 42.64% | 127.72% | 27.26% | 5.02% | −81.46% | −39.20% | −29.83% | −95.40% | — | — | −48.34% | −98.45% | −118.25% | −213.61% |
| Basic EPSper basic share | $0.15 | $0.01 | -$6.45 | $1.13 | $3.26 | $0.67 | $0.14 | -$1.85 | -$0.78 | -$0.56 | -$1.00 | -$1.39 | -$2.35 | -$0.68 | -$0.65 | -$0.59 | -$10.00 |
| Diluted EPSper diluted share | $0.15 | $0.01 | -$6.45 | $0.96 | $3.21 | $0.66 | $0.14 | -$1.85 | -$0.78 | -$0.56 | -$1.00 | -$1.39 | -$2.35 | -$0.68 | -$0.65 | -$0.59 | -$10.00 |
Owners
Reported shareholders
10.77%of listed shares
BlackRock, Inc.17.79M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.77%17.79M shares |
ARMISTICE CAPITAL, LLC | 8.43%13.93M shares |
Sarissa Capital Management LP | 5.56%9.19M shares |
STATE STREET CORP | 5.33%8.81M shares |
BANK OF AMERICA CORP /DE/ | 5.26%8.68M shares |
RENAISSANCE TECHNOLOGIES LLC | 4.84%7.99M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.00%6.61M shares |
AQR CAPITAL MANAGEMENT LLC | 3.91%6.47M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.54%5.85M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.34%5.51M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.92%4.83M shares |
TWO SIGMA INVESTMENTS, LP | 2.76%4.56M shares |
MARSHALL WACE, LLP | 2.60%4.29M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 2.46%4.07M shares |
GOLDMAN SACHS GROUP INC | 2.01%3.31M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.00%3.3M shares |
FEDERATED HERMES, INC. | 1.96%3.23M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.83%3.02M shares |
DIMENSIONAL FUND ADVISORS LP | 1.53%2.52M shares |
MACKENZIE FINANCIAL CORP | 1.43%2.37M shares |
Percentages use 165.24M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 · 10b5-1 | McHugh JulieDirector | SellClass A Common Stock | 21.6K | $3.73 | $80.5K | 250.7K |
| Mar 17, 2026Form 4 | DENNER ALEXANDER JDirector | SellClass A Common Stock · indirect | 5.8K | $3.31 | $19.2K | 9.19M |
| Mar 17, 2026Form 4 | DENNER ALEXANDER JDirector | SellClass A Common Stock · indirect | 6.72M | $3.05 | $20.51M | 9.19M |
| Feb 24, 2026Form 4 | Martini Gregory S.Chief Financial Officer | SellClass A Common Stock | 11.5K | $3.66 | $41.9K | 160.6K |
| Feb 24, 2026Form 4 | John MinardoChief Legal Officer | SellClass A Common Stock | 19.1K | $3.66 | $69.7K | 363.9K |